Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells.
amino acids
leukaemic stem cells
metabolism
therapy resistance
Journal
EMBO reports
ISSN: 1469-3178
Titre abrégé: EMBO Rep
Pays: England
ID NLM: 100963049
Informations de publication
Date de publication:
09 10 2023
09 10 2023
Historique:
revised:
24
06
2023
received:
12
10
2022
accepted:
03
07
2023
medline:
10
10
2023
pubmed:
25
7
2023
entrez:
25
7
2023
Statut:
ppublish
Résumé
To fuel accelerated proliferation, leukaemic cells undergo metabolic deregulation, which can result in specific nutrient dependencies. Here, we perform an amino acid drop-out screen and apply pre-clinical models of chronic phase chronic myeloid leukaemia (CML) to identify arginine as a nutrient essential for primary human CML cells. Analysis of the Microarray Innovations in Leukaemia (MILE) dataset uncovers reduced ASS1 levels in CML compared to most other leukaemia types. Stable isotope tracing reveals repressed activity of all urea cycle enzymes in patient-derived CML CD34
Identifiants
pubmed: 37489735
doi: 10.15252/embr.202256279
pmc: PMC10561355
doi:
Substances chimiques
Arginine
94ZLA3W45F
Banques de données
GEO
['GSE226887']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e56279Subventions
Organisme : Cancer Research UK
ID : A25142
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C596/A17196
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A31287
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C57352/A29754
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A23982
Pays : United Kingdom
Informations de copyright
© 2023 The Authors. Published under the terms of the CC BY 4.0 license.
Références
Sci Transl Med. 2021 Sep 29;13(613):eabd5016
pubmed: 34586834
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Cancer Discov. 2016 Nov;6(11):1248-1257
pubmed: 27630125
Nucleic Acids Res. 2016 Jan 4;44(D1):D917-24
pubmed: 26507857
Cancer Discov. 2017 Jul;7(7):716-735
pubmed: 28416471
Nat Cell Biol. 2018 Jul;20(7):775-781
pubmed: 29941933
Nature. 2015 Nov 19;527(7578):379-383
pubmed: 26560030
Cell. 1984 Jul;37(3):1035-42
pubmed: 6204766
Blood. 2013 Aug 15;122(7):1293-304
pubmed: 23836560
Cancer Res. 2007 Jan 1;67(1):309-17
pubmed: 17210712
Leukemia. 2016 Aug;30(8):1648-71
pubmed: 27121688
Sci Rep. 2018 Aug 14;8(1):12096
pubmed: 30108309
Cancer Cell. 2011 Nov 15;20(5):674-88
pubmed: 22094260
Sci Adv. 2019 Jan 02;5(1):eaau7314
pubmed: 30613774
J Clin Invest. 2011 Jan;121(1):396-409
pubmed: 21157039
Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14147-52
pubmed: 25122679
Blood. 2010 Sep 23;116(12):2103-11
pubmed: 20554971
Nature. 2017 Nov 16;551(7680):384-388
pubmed: 29144447
Nature. 1973 Jun 1;243(5405):290-3
pubmed: 4126434
Oncotarget. 2013 May;4(5):715-28
pubmed: 23651669
Nature. 2016 Jun 08;534(7607):341-6
pubmed: 27281222
J Clin Oncol. 2010 May 20;28(15):2529-37
pubmed: 20406941
Nat Med. 2017 Jan;23(1):120-127
pubmed: 27869804
Blood. 2018 Apr 12;131(15):1639-1653
pubmed: 29463564
Exp Hematol. 2017 Apr;48:41-49
pubmed: 28087429
Biomed Pharmacother. 2019 Oct;118:109210
pubmed: 31330440
Blood. 2015 Apr 9;125(15):2386-96
pubmed: 25710880
Cell. 1984 Jan;36(1):93-9
pubmed: 6319012
Nat Med. 2017 Oct;23(10):1234-1240
pubmed: 28920959
Leukemia. 2006 Jun;20(6):1028-34
pubmed: 16617318
Invest New Drugs. 2013 Feb;31(1):99-107
pubmed: 22426640
Cell Stem Cell. 2021 Nov 4;28(11):1982-1999.e8
pubmed: 34450065
Blood. 2012 Feb 9;119(6):1501-10
pubmed: 22184410
J Vis Exp. 2016 Apr 14;(110):
pubmed: 27168390
Semin Hematol. 1995 Apr;32(2):152-8
pubmed: 7652582
EMBO Rep. 2023 Oct 9;24(10):e56279
pubmed: 37489735
Int J Cancer. 2019 Oct 15;145(8):2201-2208
pubmed: 30485425
Cell Rep. 2021 May 11;35(6):109101
pubmed: 33979616
Commun Biol. 2018 Oct 26;1:178
pubmed: 30393775
Cell Rep. 2017 Jan 24;18(4):991-1004
pubmed: 28122247
Blood. 2007 Jan 1;109(1):58-60
pubmed: 16973963